ID   SDAR1
AC   CVCL_AV63
DR   cancercelllines; CVCL_AV63
DR   Wikidata; Q54952711
RX   CelloPub=CLPUB00321;
RX   PubMed=25675381;
RX   PubMed=29846633;
RX   PubMed=30737244;
WW   http://www.mayo.edu/research/documents/follicular-thyroid-carcinoma/doc-20088094
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Val54fs (c.160delG); Zygosity=Homozygous (PubMed=29846633; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=29846633; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg282Pro (c.845G>C); ClinVar=VCV000376659; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=29846633; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 8 (PubMed=29846633)
ST   D13S317: 8,12 (PubMed=30737244)
ST   D16S539: 11
ST   D18S51: 16
ST   D21S11: 30
ST   D3S1358: 17
ST   D5S818: 13
ST   D7S820: 9,10
ST   D8S1179: 14
ST   FGA: 27
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C8054; Thyroid gland follicular carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_AV64 ! SDAR2
OI   CVCL_AV65 ! SDAR3
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 19-12-24; Version: 14
//
RX   CelloPub=CLPUB00321;
RA   Marlow L.A., Rohl S.D., Kennedy G.T., Milosevic D., Grebe S.K.G.,
RA   Reddi H.V., Eberhardt N.L., Morris J.C., Trujillo M.A., McDonough S.J.,
RA   McIver B., Bible K.C., Casler J.D., Smallridge R.C., Copland J.A. 3rd;
RT   "Newly characterized follicular thyroid carcinoma cell lines
RT   demonstrate antitumor synergy in response to combined MEK and AKT
RT   inhibitors.";
RL   (In conference) 82nd annual meeting of the American Thyroid Association; pp.A61-A61; American Thyroid Association; Quebec; Canada (2012).
//
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. 3rd;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
//
RX   PubMed=29846633; DOI=10.1210/jc.2017-01845; PMCID=PMC6126888;
RA   Marlow L.A., Rohl S.D., Miller J.L., Knauf J.A., Fagin J.A., Ryder M.,
RA   Milosevic D., Netzel B.C., Grebe S.K.G., Reddi H.V., Smallridge R.C.,
RA   Copland J.A. 3rd;
RT   "Methodology, criteria, and characterization of patient-matched thyroid
RT   cell lines and patient-derived tumor xenografts.";
RL   J. Clin. Endocrinol. Metab. 103:3169-3182(2018).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//